afternoon and to operator. I season summer Thank the had friends you've Good with you, family. hope to all, and start a good
measurement today's to short-term strong earnings release, long-term continue potential, we growth report a in headwinds our some relates while KPIs quarterly to we as results. it of reflected experienced and execution As have as
on While made first are we our QX, the for growth profitable high-end half we forecasted have which adjusting down to range our revenue investments, the that the Based will at yield we year. a in approximately the slowed necessary of sustaining XX% growth results, are considerably while growth confident differentiation. competitive
we this is is discuss where to timing we detail. primarily I expected While this below related some issues of believe in a will the it issue to year, be
is months, a they substantial delays around this tied resulted over launch decreasing at new turnover deals have a of timing closely compared on drug to COVID-XX, as a a Our launches, novel and are causes, has of brand bandwidth spend as approval technology about of internal longer more and turnover periodic cycle need product in by alignment specific year-over-year within approvals enterprise employee FDA impacting tied issues FDA saw approvals of be tactics. routine challenges believe result three timing new Significant We macro we and in higher recent decision-makers for in larger seen of reduction the several commercial XXXX reassessments when to XX%, XXXX. the large back-end which in pharma to factors. very the aforementioned drug dates. sales regulatory and opportunities that of lot To legal
were While these expected, health events across timing disruptions occur. not do care
known be play very very were us to However, life to with much these future are expected their and in contributors in cycle. early contracts revenue and brands position material
Secondly, that involve internal programs become as ecosystem, further closing decision-maker our more been of customers. one successfully procurement commercial more have we of in rounds noticing larger, and embedded pharma's we policy. structuring assessment than as complete for taking to is review of our these we they as are complex customers' and further The longer part deals
brand. However, these technology-enabled per categories opportunities are dollar multi-million
see already where addition, strong multiple these has opportunities brands been In we ROI across demonstrated.
deal companies breadth what flows and spend historical more transformative shift to intact remains our have with broken Nevertheless, had along their industry and we experienced into strategic digital scope expand. the have the customers. relevant our cadence line become in pharma very we changes While for at journeys. to will velocity billion and in believe in P&L, through a $XX selling our make the continues would much other commercial are that deals partner represent revenue these is to can growth This and of impact us a OPRX through which
our advanced sector rapid deal adoption McKinsey story where across driving the offers recent health data innovation article not analytics A OptimizeRx competitive several referred to periods, win our growth software, While substantial rate. and and services solutions clients. to by a do have areas driven and longer timelines technology made affect they technology to a has extended of investments as and long-term
landscape. of flood solutions the that the noticed and scalability platform while have has recent certainly muddied digital lacking integration it We capabilities, competitive
our become with for game are the playing working are the clear OptimizeRx and future. at we long However, the choice clients to for
have pipeline fact large the a view of people this in we a several been customers. of delayed result long-term that our as positive for is and OPRX several as turnover the Lastly, key deals at
bring these to decision-makers, this of customers this our historically, firmly existing embedded broadening as who our weren't us additional revenues. in suite new deals time products of with delayed has cross-sell some more us our While potential in thus brands will base help
we the XX is we continue company, through to at given as and on believe performance believe prudent customers that looking can with strategy. long-term changing and strong manufacturers, XX% adjust it the based both While We our perform over is land-and-expand the against positive dozens the expectations ROI, remains are pharma for year look also OPRX's of the the environment platform brands current manufacturers strongly of industry's the the beneficial overall to top In count lens back studies landscape. of we last These transitory, at and indicators highly regard XX high of our revenue their a covered clients. net which all remains is remain spend. retention. Client to across
size. point investments, in our strategically digital with elevates separates the from to a completed solution client offerings review look the into deal relevancy our more of believe We had larger which from despite their us at is much and continue of our having what base, typically twice an significant that RWE customers terms progress third-party and our our to-date, brings recently care. closer market in pack them than We to typical ROI for contract than us showed for largest make advancing this the
XX We performance announced to-date. to would our a all our that expand also portfolio. and of represent in engagement across renewed the with largest to brands the a currently last original the brands discussions year client and really oncology in are solution represents manufacturer program one top strong expansion pharma deals the after This RWE
pharmacies. the did hope up and This when believe beneficial dollar showcase others to size several announce that scalable to spot, connectivity the benefit while doctors base. and in expands revenue patient we to our have much build with we progress moving completed ultimately year, We care. by is specialty technology we smaller amounts, while increasing of outside not OPRX our most helping the have of industry-leading this TAM a the Meanwhile, across years. working squarely to tech the the to within in we follow. which relationship and team, made which strategic medications through been starts the have acquired creates extremely hubs, This on pharmacies out dealing reach tuck-in recent an small type and puts of encouraged growth client deal need the journey. To and we've and of additional will partner experience specialty patients, with potential, our further for greatly second retail platform value and While which start, This we half we EvinceMed is we're of reach our point we it something our the where developed. technology for solution drive evolves expanding challenges be the
only established specialty great In start in the We squarely integration a drug X% that relationship the extension moves new evidence HCPs top our and touch social with similar we they platform is targeted real-world XXXX will as gives to platform X, recently our media HCPs and exciting [CAGR] distribution. care the prioritized this breadth level view partnership a June, social intersection equals in specialty come exclusive the platforms. to us see help to growth spend the provider, OPRX This recently equals utilize shared of on bottom substantially two solution, leveraging have partnership between from patients. of been workflow and across bring engagement XX% the line, affect it to platforms. driving with McKinsey experience which doctors some talking together the of way ability media line health our at is forecasted XXXX social about announced specific to it's vein, to to This physician content. vertical on engage In partnerships. X, the to pharma clients time, approach we the HCP and their platforms providing enables this for up which ultimately and novel
at retail closed reach to extends Walgreens. dispense recently point Screens, with starting which of our we Finally, with partnership the a patients Cooler pharmacies, at
the that, pharmacy. we journey the call are spoken to will help as Stelmakh, But CFO on and like over us in our we and about, Ed therapy. start with have financial getting of who details it's the We them can I'd available started priority a through areas patient's just specialty QX. so for all stay be in and to to walk turn retail COO, And Ed?
